Get the Stockscreener App
2.88
1.77%
0.05
After Hours:
2.93
0.05
+1.74%
Veru Inc stock is traded at $2.88, with a volume of 285.70K.
It is up +1.77% in the last 24 hours and down -15.29% over the past month.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
See More
Previous Close:
$2.83
Open:
$2.83
24h Volume:
285.70K
Relative Volume:
0.16
Market Cap:
$46.22M
Revenue:
$3.86M
Net Income/Loss:
$-19.20M
P/E Ratio:
-3.9571
EPS:
-0.7278
Net Cash Flow:
$-24.88M
1W Performance:
-7.99%
1M Performance:
-15.29%
6M Performance:
+21.52%
1Y Performance:
-50.65%
1-Day Range:
$2.76
$2.95
1-Week Range:
$2.7001
$3.3499
52-Week Range:
$2.05
$7.33
Veru Inc Stock (VERU) Company Profile
Name
Veru Inc
Sector
Industry
Phone
(312) 595-9123
Address
2916 N. MIAMI AVENUE, MIAMI, FL
Compare VERU vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
2.88 | 45.42M | 3.86M | -19.20M | -24.88M | -0.7278 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Canaccord Genuity | Buy |
| May-14-24 | Initiated | B. Riley Securities | Buy |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Jun-07-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Feb-09-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jul-03-18 | Initiated | Maxim Group | Buy |
View All
Veru Inc Stock (VERU) Latest News
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day - Yahoo Finance UK
Price to sales forward of Veru Inc. – NASDAQ:VERU - TradingView
VERU Q2 2026 Earnings: Narrower-than-expected loss highlights cost control progressEarnings Power Value - dars.gov.et
Veruto Offer and Sell up to $21.8 Mln of C - Moomoo
Veru Establishes At-the-Market Equity Offering Program - TipRanks
Veru Launches $21.8 Million At-The-Market Equity Program With Oppenheimer and Canaccord - TradingView
Veru (NASDAQ: VERU) launches $21.8M at-the-market common stock offering - Stock Titan
Veru Inc. (NASDAQ: VERU) to sell up to $21.8M in common stock via ATM - Stock Titan
VERUVeru Inc Volatility & Greeks - Finviz
VERU Q1 2026 Earnings: Narrower-than-Expected Loss Exceeds EstimatesEarnings Stability Report - dars.gov.et
Veru Inc.(NasdaqCM: VERU) added to Russell Microcap Value Benchmark Index - marketscreener.com
Veru Inc.(NasdaqCM: VERU) added to Russell 3000E Index - marketscreener.com
Veru Inc.(NasdaqCM: VERU) added to Russell Microcap Index - marketscreener.com
Enterprise value to EBITDA forward of Veru Inc. – NASDAQ:VERU - TradingView
Enterprise value to revenue forward of Veru Inc. – NASDAQ:VERU - TradingView
Price to earnings forward of Veru Inc. – NASDAQ:VERU - TradingView
Enterprise value to revenue forward of Veru Inc – GETTEX:FMW0 - TradingView
Veru Inc Actuals & Estimates (NASDAQ:VERU) - TradingView
Price to book forward of Veru Inc – GETTEX:FMW0 - TradingView
Price to sales forward of Veru Inc – GETTEX:FMW0 - TradingView
Price to earnings forward of Veru Inc – GETTEX:FMW0 - TradingView
A41ES4 Forecast — Price Target — Prediction for 2027 - TradingView
VERU Forecast — Price Target — Prediction for 2027 - TradingView
Veru Inc (VERU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Veru Inc (VERU) Institutional Confidence - TradingKey
Veru Inc (VERU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Veru Inc (VERU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Earnings call transcript: Veru Inc Q2 2026 shows improved financials - MSN
Veru Inc (VERU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Veru Inc (VERU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Veru Inc (VERU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Veru Inc (VERU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Veru Inc (VERU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
This small-cap biotech just soared over 160% — what is the Novo Nordisk connection? - MSN
Veru teams up with Novo Nordisk for obesity combination therapy trial (VERU) - MSN
Veru Inc. (VERU) Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock Declines Amid Pre-Revenue StatusSaaS Earnings Trends - newsline.com
Why is Veru stock rising 10% today? By Investing.com - Investing.com Canada
Why is Veru stock rising 10% today? - Investing.com
VERU Q1 2026 Earnings: EPS Beat by 58.72% Amidst Market SkepticismPre-Earnings Setup - newsline.com
Wall Street sees huge upside as Novo Nordisk backs biotech company - thestreet.com
Veru And 2 Other Intriguing Penny Stocks To Watch - Sahm
Novo Nordisk's Mixed Bag: Zenagamtide Data Delights, CagriSema Stumbles, Veru Deal Emerges - AD HOC NEWS
Novo Nordisk Wegovy Trial With Veru Adds Underappreciated Obesity Angle - Sahm
Veru (NASDAQ: VERU) Stock Price Surges Over 160% After Clinical Supply Deal With Novo Nordisk (NYSE: NVO) - foreignpolicyjournal.com
Veru (VERU) Stock; Surges 88% as Novo Nordisk Partners on Wegovy-Supported Clinical Trial - MEXC
Veru Stock Surges 167% After Novo Nordisk Backs Its Obesity Drug - MEXC
Veru (VERU) Stock Rockets 167% on Novo Nordisk Obesity Drug Partnership - MEXC
Veru stock holds at Outperform as Oppenheimer cites Novo deal By Investing.com - Investing.com Australia
Veru Shares Pop on Novo Wegovy Tie-Up, Uncertainty Lingers Over Key Clause - TechStock²
Veru (VERU) Stock Explodes 167% on Novo Nordisk Obesity Drug Partnership - MoneyCheck
Veru Inc Stock (VERU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):